# Cathie Wood's Potential 2024 Stock Winners $GH $BEAM $DNA $NTLA

Live Trading News is an independent financial media publication. Masthead: Live Trading News. Parent: Knightsbridge Group. Product cousin: KXCO (kxco.ai). Coverage: markets, policy, AI, quantum, blockchain, FX, biotech, ASEAN. New stories are signed ML-DSA-65 and anchored on Armature L1; articles published before the platform launch are not signed. Nothing on the site is investment advice.

Canonical HTML: https://www.livetradingnews.com/cathie-woods-potential-2024-stock-winners-gh-beam-dna-ntla
Last modified: 2024-01-09

---

By Shayne Heffernan · 2024-01-09
Tags: Shayne Heffernan on Investments, Stocks, stocks, Bullish, Headline News, shayne heffernan, Shayne Heffernan, Education, Strategy, Opinion, Shayne Heffernan, WallStreet, Featured, Must Read, Most Popular, 2024, Club 88
Signed: no (published before platform launch).
Nothing in this article is investment advice.

In 2023, Cathie Wood showcased remarkable prowess with her Ark Innovation ETF (NYSEMKT: ARKK) witnessing a 67% surge, while the Ark Next Generation Internet ETF (NYSEMKT: ARKW) outpaced with a stellar 97% rise.

Now, as projections unfold for [2024](https://www.club88.vip), analysts anticipate significant growth potential for some stocks within Wood's portfolio, as depicted in the table below:

Stock Name

Ticker Symbol

2023 Performance

Average 12-Month Price Target

Expected Upside

Guardant Health

GH

Slightly Down

83%

High

Beam Therapeutics

BEAM

-30%

85%

Moderate

Ginkgo Bioworks

DNA

No Change

120%

High

Intellia Therapeutics

NTLA

-13%

168%

Very High

1. **Guardant Health**: Despite its 2023 performance, analysts foresee an 83% rise, with unanimous buy or strong buy ratings.
2. **Beam Therapeutics**: A 30% dip in 2023 hasn't deterred optimism, with an 85% potential upside despite some analyst downgrades.
3. **Ginkgo Bioworks**: Stable performance in 2023, but projections suggest a 120% increase, though opinions on the stock are divided.
4. **Intellia Therapeutics**: Despite a 13% drop last year, an impressive 168% potential upside is predicted, highlighting its significant potential.

**Conclusion**: While Wall Street's projections are ambitious, it's essential to approach these forecasts with caution. The lackluster 2023 performances of these stocks amidst a soaring market is a reminder that unforeseen macroeconomic factors can influence outcomes. However, Cathie Wood's long-term vision for these companies, considering their revolutionary technologies in early cancer detection, DNA modification, cell engineering, and gene editing, could be the real value proposition. Time will tell if [Wall Street's 2024 ](https://www.livetradingnews.com/the-case-for-the-sp-500-reaching-5000-by-the-end-of-2024-spy-224123.html)predictions align with Wood's long-term strategy.

Shayne Heffernan

---

This Markdown mirrors https://www.livetradingnews.com/cathie-woods-potential-2024-stock-winners-gh-beam-dna-ntla. The HTML page is canonical.
Site index for AI clients: https://www.livetradingnews.com/llms.txt